de Carsalade G Y, Wallach D, Spindler E, Pennec J, Cottenot F, Flageul B
Clinique des Maladies Cutanees du Pr. L. Dubertret, Hopital Saint-Louis, Paris, France.
Int J Lepr Other Mycobact Dis. 1997 Mar;65(1):37-44.
Between 1980 and 1994, 67 new or relapsing leprosy patients were treated by daily administered multidrug regimens. Tuberculoid patients (23 TT/BT) received either bitherapy [rifampin + dapsone or clofazimine (RMP + DDS or CLO)] or tritherapy [RMP + DDS and/or CLO and/or ethionamide (ETH)] until clinical cure. Lepromatous patients (44 BB/BL/LL) received tritherapy (RMP + DDS and/or CLO and/or ETH) at least until bacteriological negativity. Of the 23 tuberculoid patients only one patient (5%) was cured at 6 months and about 70% needed between 6 and 24 months of treatment to obtain clinical cure (mean 19.5 months). In the 44 lepromatous patients, the achievement of bacteriological negativity was significantly linked to the initial bacterial index (BI), and it occurred after 2 to 7 years (mean 66.5 months) of multidrug therapy (MDT). The average BI decrease per year was 1.1+ during the first year, 0.9+ the second year, and then < 0.5+ per year. Reactional states significantly (p < 0.01) influenced the BI course: reversal reactions (RR) accelerated while erythema nodosum leprosum (ENL) delayed the BI decrease. Three of the 23 (13%) tuberculoid and 19 of the 44 (43%) lepromatous patients (p < 0.02) exhibited a RR and 18 of 44 (41%) lepromatous patients had ENL during MDT. A late RR (LRR) was observed in 1 (5%) and 6 (17%) of our tuberculoid and lepromatous patients, respectively, and 3 (8%) of our lepromatous patients suffered post-MDT ENL. No confirmed relapse has been observed within a follow-up period of 6 months to 7 years and 3 months [59 person-years at risk (PYR)] for TT/BT patients and of 4 months to 5 years and 10 months (100 PYR) for BB/BL/LL patients. When compared to the recommended WHO/MDT, it appears that daily MDT does not increase the clinical or the bacteriological cure rates either at 6 months in paucibacillary tuberculoid patients or at 2d years in multibacillary lepromatous patients. Moreover, as does the WHO/MDT, our regimens show a high frequency of reactional states both during and after treatment. This fact constitutes the main new problem of the actual treatment of leprosy.
1980年至1994年间,67例新诊断或复发的麻风病患者接受了每日给药的多药联合治疗方案。结核样型患者(23例TT/BT)接受二联疗法[利福平+氨苯砜或氯法齐明(RMP+DDS或CLO)]或三联疗法[RMP+DDS和/或CLO和/或乙硫异烟胺(ETH)]直至临床治愈。瘤型患者(44例BB/BL/LL)接受三联疗法(RMP+DDS和/或CLO和/或ETH)至少直至细菌学转阴。23例结核样型患者中,仅1例患者(5%)在6个月时治愈,约70%的患者需要6至24个月的治疗才能获得临床治愈(平均19.5个月)。在44例瘤型患者中,细菌学转阴与初始细菌指数(BI)显著相关,且发生在多药联合治疗(MDT)2至7年(平均66.5个月)后。第一年BI平均每年下降1.1+,第二年为0.9+,之后每年<0.5+。反应状态对BI进程有显著影响(p<0.01):逆转反应(RR)加速而麻风结节性红斑(ENL)延缓BI下降。23例结核样型患者中有3例(13%)、44例瘤型患者中有19例(43%)出现RR(p<0.02),44例瘤型患者中有18例(41%)在MDT期间发生ENL。在我们的结核样型和瘤型患者中,分别有1例(5%)和6例(17%)出现迟发性RR(LRR),3例(8%)瘤型患者在MDT后发生ENL。在6个月至7年零3个月的随访期内(TT/BT患者59人年暴露时间)以及4个月至5年零10个月的随访期内(BB/BL/LL患者100人年暴露时间),未观察到确诊的复发。与世界卫生组织推荐的MDT相比,每日MDT似乎在少菌型结核样型患者6个月时或多菌型瘤型患者2年时并未提高临床或细菌学治愈率。此外,与世界卫生组织的MDT一样,我们的治疗方案在治疗期间和治疗后反应状态的发生率都很高。这一事实构成了当前麻风病治疗的主要新问题。